Recent News

Dynavax Initiates Phase 3 Study of HEPLISAV-B(TM)

April 15, 2014

Dynavax Reports Fourth Quarter and Year End 2013 Financial Results

March 10, 2014

Dynavax Announces Withdrawal of European Marketing Application for HEPLISAV(TM)

February 18, 2014

Dynavax to Present at the 32nd Annual J.P. Morgan Healthcare Conference

January 10, 2014

Dynavax Announces Submission of Responses to EMA Day 120 List of Questions for HEPLISAV(TM) MAA

December 19, 2013

More...

Clinical-Stage Pipeline

Our clinical-stage pipeline includes product candidates for the prevention and treatment of infectious diseases. More...

Focused on Infectious Diseases

Scientific expertise and proprietary technologies drive our discovery and development of novel Toll-like Receptor (TLR) based product candidates. Our focus is on serious medical needs in the prevention and treatment of infectious diseases.  

Leading Partners

Our partnerships with leading pharmaceutical companies, including GlaxoSmithKline and AstraZeneca, and our funding agreements support our commitment to discover and develop TLR-based products to address serious medical needs.

Integrated European Subsidiary

Rhein Biotech, our European subsidiary, manufactures hepatitis B surface antigen for our lead product, HEPLISAV hepatitis B vaccine. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.